|
1
|
Pavlidis N and Fizazi K: Cancer of unknown
primary (CUP). Crit Rev Oncol Hematol. 54:243–250. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Varadhachary GR, Abbruzzese JL and Lenzi
R: Diagnostic strategies for unknown primary cancer. Cancer.
100:1776–1785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Altman E and Cadman E: An analysis of 1539
patients with cancer of unknown primary site. Cancer. 57:120–124.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavdilis N, Briasoulis E, Hainsworth J and
Greco FA: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 30:1990–2005. 2003.
|
|
5
|
Golfinopoulos V, Pentheroudakis G, Salanti
G, Nearchou AD, Ioannidis JP and Pavlidis N: Comparative survival
with diverse chemotherapy regimens for cancer of unknown primary
site: Multiple-treatments meta-analysis. Cancer Treat Rev.
35:570–573. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Varadhachary GR, Talantov D, Raber MN,
Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, et
al: Molecular profiling of carcinoma of unknown primary and
correlation with clinical evaluation. J Clin Oncol. 26:4442–4448.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su AI, Welsh JB, Sapinoso LM, Kern SG,
Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF
Jr and Hampton GM: Molecular classification of human carcinoma by
use of gene expression signatures. Cancer Res. 61:7388–7393.
2001.PubMed/NCBI
|
|
8
|
Greco FA and Hainsworth JD: Cancer of
unknown primary siteCancer: Principles & Practice of Oncology.
DeVita VT Jr, Hellman S and Rosenberg SA: 6th. Lippincott Williams
& Wilkins; Philadelphia: pp. 2537–2560. 2001
|
|
9
|
Van de Wouw AJ, Janssen-Heijnen ML,
Coebergh JW and Hillen HF: Epidemiology of unknown primary tumours;
incidence and population-based survival of 1285 patients in
Southeast Netherlands, 1984–1992. Eur J Cancer. 38:409–413. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hess KR, Abbruzzese MC, Lenzi R, Raber MN
and Abbruzzese JL: Classification and regression tree analysis of
1000 consecutive patients with unknown primary carcinoma. Clin
Cancer Res. 5:3403–3410. 1999.PubMed/NCBI
|
|
11
|
Harada H, Yamashita Y, Kuraoka K and
Taniyama K: Sequential mediastinal lymphadenectomy of an unknown
primary tumor. The Ann Thorac Surg. 95:687–689. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakano T, Endo S, Endo T, Hasegawa T,
Nakayama M, Sugiyama Y and Hironaka M: Multimodal treatment for
multistation mediastinal lymph node adenocarcinoma: A case report.
Ann Thorac Cardiovasc Surg. 18:136–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
SorghoLougue LC, Luciani A, Kobeiter H,
Zelek L, Malhaire C, Deux JF, Brun B, Piedbois P and Rahmouni A:
Adenocarcinomas of unknown primary (ACUP) of the mediastinum
mimicking lymphoma: CT findings at diagnosis and follow-up. Eur J
Radiol. 59:42–48. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pepper C, Pai I, Hay A, Deery A, Wilson P,
Williamson P and Pitkin L: Investigation strategy in the management
of metastatic adenocarcinoma of unknown primary presenting as
cervical lymphadenopathy. Acta Otolaryngol. 134:838–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Briasoulis E, Kalofonos H, Bafaloukos D,
Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C,
Kosmidis P and Pavlidis N: Carboplatin plus paclitaxel in unknown
primary carcinoma: A phase II Hellenic cooperative oncology group
study. J Clin Oncol. 18:3101–3107. 2000.PubMed/NCBI
|
|
16
|
Culine S, Lortholary A, Voigt JJ, Bugat R,
Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B,
et al: Cisplatin in combination with either gemcitabine or
irinotecan in carcinomas of unknown primary site: Results of a
randomized phase II study-trial for the French study group on
carcinomas of unknown primary (GEFCAPI 01). J Clin Oncol.
21:3479–3482. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Erlander MG, Ma XJ, Kesty NC, Bao L,
Salunga R and Schnabel CA: Performance and clinical evaluation of
the 92-gene real-time PCR assay for tumor classification. J Mol
Diagn. 13:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meiri E, Mueller WC, Rosenwald S, Zepeniuk
M, Klinke E, Edmonston TB, Werner M, Lass U, Barshack I, Feinmesser
M, et al: A second-generation microRNA-based assay for diagnosing
tumor tissue origin. Oncologist. 17:801–812. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Greco FA, Lennington WJ, Spigel DR,
Varadhachary GR and Hainsworth JD: Carcinoma of unknown primary
site: Outcomes in patients with a colorectal molecular profile
treated with site-specific chemotherapy. J Cancer Ther. 3:37–43.
2012. View Article : Google Scholar
|
|
20
|
Hainsworth JD, Schnabel CA, Erlander MG,
Erlander MG, Haines DW III and Greco FA: A retrospective study of
treatment outcomes in patients with carcinoma of unknown primary
site and a colorectal cancer molecular profile. Clin Colorectal
Cancer. 11:112–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Laurie SA and Licitra L: Systemic therapy
in the palliative management of advanced salivary gland cancers. J
Clin Oncol. 24:2673–2678. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barnes L, Eveson JW, Reichart P and
Sidransky D: Tumours of the Salivary GlandsWorld Health
Organization Classification of Tumors: Pathology and Genetics of
Head and Neck Tumours. World Health Organization; Lyon, France: pp.
209–282. 2005
|
|
23
|
Spiro RH: Salivary neoplasms: Overview of
a 35-year experience with 2,807 patients. Head Neck Surg.
8:177–184. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hamper K, Lazar F, Dietel M, Caselitz J,
Berger J, Arps H, Falkmer U, Auer G and Seifert G: Prognostic
factors for adenoid cystic carcinoma of the head and neck: A
retrospective evaluation of 96 cases. J Oral Pathol Med.
19:101–107. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Florentine BD, Fink T, Avidan S,
Braslavsky D, Raza A and Cobb CJ: Extra-salivary gland
presentations of adenoid cystic carcinoma: A report of three cases.
Diagn Cytopathol. 34:491–494. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaplan MJ, Johns ME and Cantrell RW:
Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg.
95:165–170. 1986.PubMed/NCBI
|
|
27
|
Dreyfuss AI, Clark JR, Fallon BG, Posner
MR, Norris CM Jr and Miller D: Cyclophosphamide, doxorubicin and
cisplatin combination chemotherapy for advanced carcinomas of
salivary gland origin. Cancer. 60:2869–2872. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Licitra L, Cavina R, Grandi C, Palma SD,
Guzzo M, Demicheli R and Molinari R: Cisplatin, doxorubicin and
cyclophosphamide in advanced salivary gland carcinoma: A phase II
trial of 22 patients. Ann Oncol. 7:640–642. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alberts DS, Manning MR, Coulthared SW,
Koopmann CF Jr and Herman TS:
Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy
for advanced carcinoma of the parotid gland. Cancer. 47:645–648.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Golfinopoulos V, Pentheroudakis G, Salanti
G, Nearchou AD, Ioannidis JP and Pavlidis N: Comparative survival
with diverse chemotherapy regimens for cancer of unknown primary
site: Multiple-treatments meta-analysis. Cancer Treat Rev.
35:570–573. 2009. View Article : Google Scholar : PubMed/NCBI
|
